FDA declines approval of Summit’s lung cancer treatment

Detailed summary

Summit Therapeutics says FDA declines ivonescimab plus chemotherapy approval for advanced lung cancer, citing insufficient evidence of longer survival.

Summit Therapeutics (SMMT) said Sunday that the U.S. Food and Drug Administration declined to approve ivonescimab combined with chemotherapy for certain patients with advanced lung cancer, citing insufficient evidence that the treatment helps patients live longer.

Opening of the article, excerpted from Seeking Alpha. To read the rest, open the article on the publisher's site.